Medical therapy is critical in preventing the worst complications of peripheral artery disease (PAD), among them heart attack ...

In this week’s View, Dr. Eagle looks at contemporary outcomes and trends for the transseptal mitral valve-in-valve procedure using balloon-expandable transcatheter valves. He then explores complete vs ...

Beta-blocker use did not result in a lower incidence of composite death or new AMI, all-cause death, AMI, or heart failure ...

Myeloperoxidase inhibition with mitiperstat in patients with heart failure (HF) with preserved or mildly reduced ejection fraction (HFpEF or HFmrEF, respectively) was safe and well-tolerated, but did ...

Norland K, Schaid DJ, Naderian M, Na J, Kullo IJ.

A new nasal spray form of bumetanide may reduce the tissue swelling caused by heart failure (HF) as effectively as the standard oral and intravenous formulations of the loop diuretic, based on ...

Zerlasiran, a short-interfering RNA, was well-tolerated and reduced time-averaged lipoprotein(a) [Lp(a)] concentration by more than 80% during 36 weeks of treatment in patients with atherosclerotic ...

Keywords: American Heart Association, AHA Annual Scientific Sessions, AHA24Slides, Visual Abstract ...

Older patients with STEMI-related cardiogenic shock have a greater risk of mortality and may not experience the same benefit from microaxial flow pump (mAFP) treatment as their younger counterparts, ...

Sodium zirconium cyclosilicate (SZC) helped to optimize spironolactone use in patients with heart failure and reduced ejection fraction (HFrEF) and hyperkalemia, based on findings from the REALIZE-K ...

The KRAKEN trial showed that among patients with high cardiovascular risk and elevated lipoprotein(a), muvalaplin reduces lipoprotein(a) levels. Patients with high cardiovascular risk and elevated ...

The ENDEAVOR trial showed that in patients with HFpEF or HFmrEF, the myeloperoxidase inhibitor mitiperstat did not improve symptoms or 6-minute walk distance. Patients with symptomatic HFpEF or HFmrEF ...